Saturday, October 26, 2013
Radisson Blu Aqua Hotel
221 N Columbus Dr.
Chicago, IL
David F. McDermott, MD - Beth Israel Deaconess Medical Center
James H. Finke, PhD - Cleveland Clinic Foundation
Sat. Oct. 26, 2013 | |
10:05 -10:10 am | Case Presentation: HD IL2 or PD1 Case Jenny Jiyun Kim, MD, MS - Johns Hopkins University |
10:10 – 10:25 am | Immune System as a Therapeutic Target in RCC Charles Drake, MD, PhD - Johns Hopkins University |
10:25 – 10:40 am | Tumor Microenvironment in RCC James H. Finke, PhD - Cleveland Clinic Foundation |
10:40 – 10:55 am | Targeting CTLA4 in RCC: Rationale and Current Data Padmanee Sharma, MD, PhD - MD Anderson Cancer Center |
10:55 - 11:10 am | Vaccines in RCC: Rrationale and Existing Data Walter Storkus, PhD - University of Pittsburgh |
11:10 – 11:25 am | PD1/PDL1 Gordon J. Freeman, PhD - Dana-Farber Cancer Institute |
11:25 – 11:40 am | Immune Biomarkers in RCC: What, When and How? David F. McDermott, MD - Beth Israel Deaconess Medical Center |
11:40 – 11:55 am | Group Discussion and Audience Participation Moderators: David F. McDermott, MD - Beth Israel Deaconess Medical Center James H. Finke, PhD - Cleveland Clinic Foundation |
The International Kidney Cancer Symposium brought together key individuals and representatives from leading laboratories and centers working with renal cell carcinoma. The symposium provided a forum for the exchange of ideas and information that will continue to frame directions for future research and treatment and is dedicated to medical oncologists, urologists, and scientists involved in the clinical and research aspects of renal cell carcinoma.